Services

Healthcare technologies reach the market only when their evidence, value proposition, commercial model, and implementation pathway reinforce one another. Charrette integrates these requirements across three connected service areas: Value Demonstration, Commercial Strategy, and Healthcare Adoption. Engagements may address a focused decision or span the full path from early validation through coverage, market entry, and routine clinical use.

Value Demonstration

We define what must be proven, to whom, and with what evidence. We then design the studies, models, and reimbursement assets required.

Translating disease epidemiology and etiology, intended use, target population, claims, comparators, and performance requirements into a sequenced evidence roadmap.

Mapping coverage policies, benefit structures, decision-makers, and evidence thresholds by payer and line of business.

Funding strategy, opportunity identification, and proposal development across federal, foundation, and international sources.

Claims-aligned analytical, clinical, and algorithmic validation, including biomarker selection, limit of detection, precision, sensitivity and specificity, reproducibility, and generalizability, where applicable.
Prospective studies and vignette-based physician research measuring actionability, changes in clinical management, workflow integration, and downstream outcomes.
EHR-, claims-, registry-, and cohort-based studies demonstrating performance in practice, comparative effectiveness, healthcare utilization, and patient outcomes.
Budget-impact, cost-effectiveness, return-on-investment, and total-cost-of-care models aligned with payer, ICER, and HTA expectations.

CPT, PLA, and HCPCS strategy, technical assessment dossiers for MolDX/other MACs and commercial payer review, payment-pathway and rate-setting support, and medical policy engagement.

Commercial Strategy

We identify the highest-value markets, customers, and use cases, then build the portfolio, pricing, partnership, and go-to-market strategy around them.

Revenue forecasting and cascade-of-care modeling that show where patients flow, where they are lost, and where the product creates value.
Physician, payer, administrator, and KOL interviews, voice-of-customer studies, and advisory board creation and facilitation.
Precise identification of who decides, who pays, who uses, and which segments offer the strongest path to adoption.
Prioritization and sequencing of indications, populations, claims, and product extensions.
Alignment of the regulatory pathway, launch sequence, site of care, delivery infrastructure, manufacturing and supply chain, distribution model, reimbursement mechanics, and capital requirements.
Willingness-to-pay research, list and net pricing, reimbursement constraints, channel economics, and value-based or risk-sharing arrangements.
Design of the operating model, sales motion, channels, distribution relationships, and health system or industry partnerships required to reach the market.
Buy-side commercial diligence for investors and acquirers, vendor diligence for companies and bankers preparing an asset for market, commercial valuation support, and post-merger integration support.

Healthcare Adoption

We establish the health system relationships, implementation pathways, and contracts needed for adoption, while engaging the KOLs, patient advocacy organizations, professional societies, and guideline bodies that influence clinical practice.

Partnerships with centers of excellence, referral networks, patient advocacy organizations, and other stakeholders that shape awareness, access, and adoption.
Designing the operational pathway for patient identification, ordering, referral, administration, results delivery, IT integration, staffing, and reimbursement.
Navigating value analysis, P&T, laboratory, capital, procurement, clinical-engineering, and IT/security reviews as applicable.
Standing up enterprise pilots, implementation studies, and strategic collaborations that establish reference accounts and create pathways to scale.
Executing GPO and IDN agreements, formulary strategy, rebate or risk-sharing arrangements, and post-contract programs that convert access into sustained utilization.
Peer-reviewed publications, congress strategy, medical education, and KOL engagement that translate evidence into clinical confidence.
Evidence packages, society engagement, and consensus-building required to influence clinical guidelines and standards of care.